biperiden has been researched along with Catatonia in 4 studies
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.
Catatonia: A neuropsychiatric disorder characterized by one or more of the following essential features: immobility, mutism, negativism (active or passive refusal to follow commands), mannerisms, stereotypies, posturing, grimacing, excitement, echolalia, echopraxia, muscular rigidity, and stupor; sometimes punctuated by sudden violent outbursts, panic, or hallucinations. This condition may be associated with psychiatric illnesses (e.g., SCHIZOPHRENIA; MOOD DISORDERS) or organic disorders (NEUROLEPTIC MALIGNANT SYNDROME; ENCEPHALITIS, etc.). (From DSM-IV, 4th ed, 1994; APA, Thesaurus of Psychological Index Terms, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Malignant catatonia, associated with different somatic and psychiatric disorders, is a rare, life-threatening syndrome." | 2.40 | [Acute life threatening catatonia--clinical significance and therapeutic possibilities]. ( Bridler, R; Hell, D, 1997) |
| "The authors describe a case report of catatonia syndrome after administration of depot neuroleptics." | 1.28 | Neuroleptic-induced catatonia: neuroleptic malignant syndrome? ( Alonso-Abolafia, A; de la Serna, I; de Leon, J; Munoz-Ruata, J; Pico-Soler, E; Saiz-Ruiz, J, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Franz, M | 1 |
| Gallhofer, B | 1 |
| Kanzow, WT | 1 |
| Bridler, R | 1 |
| Hell, D | 1 |
| de Leon, J | 1 |
| Saiz-Ruiz, J | 1 |
| Alonso-Abolafia, A | 1 |
| Pico-Soler, E | 1 |
| Munoz-Ruata, J | 1 |
| de la Serna, I | 1 |
| Kammerer, T | 1 |
| Schweitzer-Bucher, E | 1 |
| Jamet, P | 1 |
| Royer, M | 1 |
1 review available for biperiden and Catatonia
| Article | Year |
|---|---|
[Acute life threatening catatonia--clinical significance and therapeutic possibilities].
Topics: Adult; Biperiden; Catatonia; Clopenthixol; Clozapine; Diagnosis, Differential; Diazepam; Drug Admini | 1997 |
3 other studies available for biperiden and Catatonia
| Article | Year |
|---|---|
Treatment of catatonia with intravenous biperidene.
Topics: Adult; Biperiden; Catatonia; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Th | 1994 |
Neuroleptic-induced catatonia: neuroleptic malignant syndrome?
Topics: Adult; Antipsychotic Agents; Biperiden; Catatonia; Delayed-Action Preparations; Diagnosis, Different | 1990 |
[Study of the delayed-action form of a synthetic antiparkinsonian drug: Akineton].
Topics: 1-Propanol; Adolescent; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Biperiden; Catatonia; D | 1972 |